[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mechanism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mechanism":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100577173","mechanism-of-tips-to-improve-sarcopenia-100577173",false,"NCT06794853","Mechanism of TIPS to Improve Sarcopenia","Mechanism of Transjugular Intrahepatic Portosystemic Shunt to Improve Sarcopenia by Down-regulation of FGF21","Inclusion Criteria:\n\n1. Diagnosed with liver cirrhosis and needing TIPS surgical treatment;\n2. Aged between 18-80 years old;\n3. Able to understand and sign the informed consent form and willing to cooperate in completing the examinations and follow-up visits.\n\nExclusion Criteria:\n\n1. Combination of serious cardiovascular and cerebrovascular diseases (such as acute myocardial infarction, severe heart failure, etc.);\n2. Suffering from malignant tumors and in the active stage;\n3. Recent (within 3 months) history of major surgeries or traumas;\n4. The presence of mental illness or cognitive disorders, which are unable to cooperate with the study;\n5. Undergoing other special treatments that may affect the results of the study (such as certain specific immune-suppressing agents, hormones, etc.)","ALL","18 Years","80 Years",{"count":20,"type":21},132,"ESTIMATED","OBSERVATIONAL","Sarcopenia is particularly common in patients with chronic liver disease, especially in patients with decompensated cirrhosis, where the prevalence can be more than 50%. Sarcopenia is an important risk factor for a significant increase in mortality in cirrhotic patients, and is closely associated with a high incidence of complications such as hepatic encephalopathy, ascites, and infections . Recent studies have found that TIPS not only significantly improves clinical symptoms caused by portal hypertension, but may also have a positive effect on skeletal muscle mass and function in patients. Although the effect of TIPS in improving sarcopenia has been preliminarily confirmed, its mechanism is not yet fully understood. Therefore, there is an urgent need to explore the mechanism of action of TIPS to improve sarcopenia and provide guidance for clinical treatment options.",[25,26,27],"Sarcopenia","Mechanism","Cirrhosis",[29,30,31],"sarcopenia","cirrhosis","FGF21","RECRUITING","2026-02-07",{"date":35,"type":36},"2026-02-11","ACTUAL",{"date":38,"type":36},"2025-06-01",{"date":40,"type":21},"2027-12",{"name":42,"class":43},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100605334","changes-in-body-composition-of-patients-with-obesity-related-tumors-and-their-impact-on-clinical-outcomes-a-multicenter-prospective-cohort-study-100605334","NCT07161167","Changes in Body Composition of Patients With Obesity Related Tumors and Their Impact on Clinical Outcomes: a Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of gender.\n2. Histologically or cytologically confirmed obesity-associated malignant tumors (e.g., breast cancer, colorectal cancer, gastric cancer, lung cancer, or thyroid cancer) with planned treatment after diagnosis (any treatment modality permitted).\n3. No prior chemotherapy, radiotherapy, biologic therapy, immunotherapy, or other antitumor treatments for malignancy.\n\nExclusion Criteria:\n\n1. Patients with concurrent non-obesity-related malignancies.\n2. History of prior malignancy (except completely cured carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin).\n3. Patients with concurrent multiorgan dysfunction syndrome, autoimmune diseases, infectious diseases, neurological disorders, or psychiatric disorders.",true,{"count":53,"type":21},6743,"Over the past 20 years, China's obesity rates have surged, increasing cancer burden. Obesity links to 13 cancers via metabolic effects of visceral fat and insulin resistance, while sarcopenic obesity (BMI-independent) may worsen outcomes. Traditional BMI lacks precision; advanced methods (e.g., BIA\u002FCT) are needed. Existing studies show inconsistent results, possibly due to heterogeneity. This multicenter prospective cohort study uses imaging to assess body composition changes (fat\u002Fmuscle) in obesity-related tumors and their impact on survival, recurrence, and quality of life, and explore the underlying mechanism.",[56,57,58,26],"Obesity Rekated Cancer","Body Composition Changes","Survival","NOT_YET_RECRUITING","2025-09-03",{"date":62,"type":36},"2025-09-08",{"date":64,"type":21},"2025-09-15",{"date":66,"type":21},"2030-09-30",{"name":68,"class":43},"Peking Union Medical College Hospital"]